Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 31, Issue 34, 2013, Pages 4343-4348

  Cannon, Donald M ^a   Mehta, Minesh P ^b   Adkison, Jarrod B ^c   Khuntia, Deepak ^d   Traynor, Anne M ^a   Tomé, Wolfgang A ^e   Chappell, Richard J ^a   Tolakanahalli, Ranjini ^g   Mohindra, Pranshu ^a   Bentzen, Søren M ^a   Cannon, George M ^f  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Southeast Alabama Medical Center   (United States)

^d VARIAN MEDICAL SYSTEMS   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f INTERMOUNTAIN MEDICAL CENTER   (United States)

^g Juravinski Cancer Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOPSY; AXILLARY LYMPH NODE; BRONCHOCAVITARY FISTULA; BRONCHUS FISTULA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGITIS; FEMALE; FOLLOW UP; HEMOPTYSIS; HUMAN; HYPOFRACTIONATED DOSE ESCALATED RADIOTHERAPY; HYPOXEMIA; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; LUNG ABSCESS; LUNG INFILTRATE; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; LUNG VOLUME; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PNEUMONIA; RECURRENT DISEASE; RESIDUAL VOLUME; RISK FACTOR; THORAX WALL TUMOR; TRACHEOBRONCHIAL TREE; TRACHEOESOPHAGEAL FISTULA; TREATMENT DURATION; CHI SQUARE DISTRIBUTION; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIATION RESPONSE; RISK ASSESSMENT; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; RADIATION PNEUMONITIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIATION PNEUMONITIS; RADIOTHERAPY, INTENSITY-MODULATED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892900050     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.5353     Document Type: Article

References (21)

1. Perez CA, Pajak TF, Rubin P, et al: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: Report by the Radiation Therapy Oncology Group. Cancer 59: 1874-1881, 1987 (Pubitemid 17072411)
2. Cox JD, Azarnia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma - Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1555, 1990 (Pubitemid 20301186)
3. Sause W, Kolesar P, Taylor S IV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364, 2000 (Pubitemid 30111583)
4. Aupérin A, Le Péchoux C, Rolland E, et al: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-smallcell lung cancer. J Clin Oncol 28:2181-2190, 2010
5. Belderbos JS, Heemsbergen WD, De Jaeger K, et al: Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using threedimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66:126-134, 2006 (Pubitemid 44175671)
6. Willner J, Baier K, Caragiani E, et al: Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:382-389, 2002 (Pubitemid 34173001)
7. Rengan R, Rosenzweig KE, Venkatraman E, et al: Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60:741-747, 2004 (Pubitemid 39311753)
8. Kong FM, Ten Haken RK, Schipper MJ, et al: High-dose radiation improved local tumor control and overall survival in patients with inoperable/ unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63:324-333, 2005 (Pubitemid 41317147)
9. Bradley JD, Paulus R, Komaki R, et al: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small-cell lung cancer: Results on radiation dose in RTOG 0617. J Clin Oncol 31, 2013 (suppl; abstr 7501)
10. Saunders M, Dische S, Barrett A, et al: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial-CHART Steering committee. Radiother Oncol 52:137-148, 1999 (Pubitemid 29461081)
11. Bogart JA, Hodgson L, Seagren SL, et al: Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol 28:202-206, 2010
12. Mehta M, Scrimger R, Mackie R, et al: A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 49:23-33, 2001 (Pubitemid 32041273)
13. Adkison JB, Khuntia D, Bentzen SM, et al: Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: Preliminary results of a risk-stratified phase I dose escalation study. Technol Cancer Res Treat 7:441-447, 2008
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
16. Timmerman R, McGarry R, Yiannoutsos C, et al: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833-4839, 2006 (Pubitemid 46630909)
17. Timmerman R, Paulus R, Galvin J, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070-1076, 2010
18. Kong FM, Hayman JA, Griffith KA, et al: Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65:1075-1086, 2006 (Pubitemid 44202245)
19. Lee CB, Stinchcombe TE, Moore DT, et al: Late complications of high-dose ( 66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:74-79, 2009
20. Aerni MR, Parambil JG, Allen MS, et al: Nontraumatic disruption of the fibrocartilaginous trachea: Causes and clinical outcomes. Chest 130: 1143-1149, 2006 (Pubitemid 44583746)
21. Cox JD: Are the results of RTOG 0617 mysterious? Int J Radiat Oncol Biol Phys 82:1042-1044, 2012